Left Menu
Development News Edition

Bluebird prices gene therapy at 1.575 mln euros over five years

Reuters | Updated: 14-06-2019 17:36 IST | Created: 14-06-2019 17:30 IST
Bluebird prices gene therapy at 1.575 mln euros over five years
Pharmaceutical companies have been investing heavily in potentially life-changing gene therapies over the past few years, but they come with hefty price tags. Image Credit: ANI

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

The company proposed a five-year instalment plan, with 315,000 euros paid up front and additional annual payments due only if the treatment continues to be effective. Zynteglo was approved in Europe for patients age 12 and older with beta-thalassemia who require regular blood transfusions to manage their disease and have no matching donor for a stem cell transplant.

Bluebird, which is also testing Zynteglo for sickle cell disease, said it expects the therapy to be approved for beta-thalassemia in the United States in 2020. Wall Street analysts forecast Zynteglo beta thalassemia sales of about $828 million by 2024, according to data from Refinitiv. Pharmaceutical companies have been investing heavily in potentially life-changing gene therapies over the past few years, but they come with hefty price tags. As a result, some are experimenting with so-called value-based pricing, which in some cases calls for refunds if therapy fails to deliver on its promise.

Bluebird said it believes the "intrinsic value" of its one-time infusion is about $2.1 million per patient, and the price reflects the ability to avoid costly blood transfusions, improve quality of life and potentially cure patients. Patients with beta-thalassemia typically receive lifelong blood transfusions every few weeks.

Bluebird said it aims to price Zynteglo in developed nations, including the United States, within a "reasonably close" range. The company said patient access talks are underway with health authorities in Germany, Italy, France, and Britain. "The one-time potentially curative nature of what we have on our hands here sort of warrants this type of a (pricing) model in a more aggressive way," bluebird Chief Executive Officer Nick Leschly told Reuters in a phone interview.

Gene therapies use engineered viruses to carry healthy genetic material into a person's cells to replace faulty or mutated genes that cause a disease or condition. Whether these high priced new therapies can succeed in Europe, where countries have stringent price controls, remains to be seen.

The first two gene therapies were approved in Europe - UniQure NV's Glybera in 2012 for a very rare blood disorder and GlaxoSmithKline's Strimvelis in 2016 for "bubble boy" disease - and both were eventually abandoned by the companies. But drugmakers are forging ahead with promising new gene therapies that will continue to test pricing limits.

In May, Swiss drugmaker Novartis won U.S. approval for its gene therapy for spinal muscular atrophy and priced it at $2.125 million, making it the world's most expensive drug. Novartis defended the price by saying that a one-time treatment was more valuable than expensive long-term treatments. Spark Therapeutics Inc, which is being acquired by Roche Holding AG, won U.S. approval for its gene therapy to treat a rare form of blindness in 2017, pricing it at $850,000.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Download The Devdiscourse News App for Latest News.



Education post-coronavirus: Schools to rush for more digitalization

Digital education would undoubtedly boom in the post-coronavirus world, supported by educational institutions that have discovered its efficiency during the crisis, but it is still not expected to outshine traditional classroom learning....

Public health care post-COVID 19 to go for revamping, not rebooting

Until now, the economies used to classify healthcare sector under social expenditure. However, the devastation caused by COVID 19 pandemic has upgraded public healthcare on topmost priority and core economic activity for controlling future ...

Coronavirus lockdowns to speed up long-pending revamping of supply chains

With millions of production lines impacted, business disruptions to some extent are unavoidable and the lessons learned from this turbulence will leave an everlasting impact on both global and local levels of supply chains....

COVID 19 to catalyze the redefinition of urban planning and sustainability

Until now the urban planning was focused on mitigation to natural disastrous, climate change, pollution, chronic illness and lifestyle diseases. However, the global pandemic of novel coronavirus is going to change the whole narrative of urb...


Latest News

Nature takes back world's empty city streets

As humans retreat into their homes as more and more countries go under coronavirus lockdown, wild animals are slipping cover to explore the empty streets of some of our biggest cities. Wild boar have descended from the hills around Barcelon...

Syria reports first death from coronavirus

Syrias health ministry said on Sunday that a woman who died after being rushed to hospital for emergency treatment was found to have been infected by coronavirus in the first officially reported death from the disease.Syria also said its co...

Combating COVID-19: MHA suspends officers for dereliction of duty, forms 11 Empowered Groups

Union Ministry of Home Affairs MHA on Sunday suspended two officers with immediate effect and served a show-cause notice to another two officers for failing in ensuring public health and safety during the lockdown restrictions to combat COV...

Soccer-Trophy-hungry Kane says he cannot guarantee Spurs stay without progress

Tottenham Hotspur striker Harry Kane said on Sunday that he could leave the Premier League club if the team does not progress in the right direction as he wants to win trophies sooner rather than later. Kane has scored 181 goals for Spurs i...

Give Feedback